Abstract
Background: Availability of the galactose-1-phosphate uridyltransferase (GALT) assay for newborn (NB) screening has improved identification of classic galactosemia. Previously defined critical cutoffs for total galactose (Gal), typically 1.110 mmol/L (20 mg/dL), are still in use in laboratories measuring total Gal for the diagnosis of nonclassic galactosemias. Urgent notification/referral to a treatment center follows, although few of the NBs will need treatment. Methods: We reviewed all NB galactosemia-screening results and their corresponding clinical outcomes over a 5-year period (first phase, 1.32 × 106 NBs) and then over a 2-year period (second phase, 274 960 NBs). Each NB was screened for Gal and GALT. When Gal was increased and/or GALT was deficient, testing for percentage galactose-1-phosphate and/or DNA testing for common GALT mutations were performed. Results: Of 209 reported positive results, 89% did not indicate GALT deficiency. These non–GALT-deficient results represented mostly clinically benign cases with a Gal threshold of ≥1.110 mmol/L (≥20 mg/dL). The positive predictive value of a GALT cutoff of ≤40 μmol/L was 83%. After a protocol change that redefined a critical result as a GALT value ≤40 μmol/L and/or a Gal value ≥1.665 mmol/L (≥30 mg/dL), results were monitored for an additional 2 years. The new protocol dramatically reduced the number of urgent calls/referrals and reduced the total number of referrals by nearly half. Conclusions: Use of a GALT cutoff of ≤40 μmol/L/L and a Gal cutoff of ≥1.665 mmol/L (≥30 mg/dL) for urgent notification/referral dramatically reduces false positives and unnecessary follow-up, thereby reducing the stress on healthcare resources.